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Evidence-based strategies to improve the hepatitis B virus (HBV) vaccination coverage rates
might help to reduce the burden caused by co-infection with HBV and human immuno-
deﬁciency virus (HIV). In this study, the aim was to evaluate the vaccination coverage and
immunity against HBV among HIV-infected individuals in South Brazil, and identify fac-
tors  that are associated with compliance patterns and antibody reactivity. Three hundred
HIV-infected men and women were included in this survey. The patients answered a stan-
dardized questionnaire, and vaccination cards were checked in order to assess hepatitis B
vaccine status. A blood sample was collected for quantitative determination of antibody to
hepatitis B virus surface antigen (anti-HBs). Participants were also evaluated for their CD4
cell  count and HIV viral load. The overall vaccination coverage of HBV vaccination found in
this study (57.4%) was lower than that was previously reported in South Brazil. Anti-HBs lev-
els >10 IU/L were observed in 47.0% of the studied population. A signiﬁcant inequality in the
coverage rates and antibody reactivity was found in favor of patients with better economicstatus. In conclusion, the results indicate the need for improvement in the HBV vaccination
coverage among HIV carriers, in particular focusing on low-income individuals.ntroductionnfection with hepatitis B virus (HBV) still constitutes a major
ublic health problem in many  countries. More than two
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billion people have been infected with HBV worldwide, result-
ing in 240 million chronic carriers. It is estimated that aboutciences Center, Federal University of Santa Catarina, University
780,000 people die annually from complications related to
hepatitis B.1 Infection with human immunodeﬁciency virus
(HIV) is also a serious global health problem. About 75 million
i s . 2 0182  b r a z j i n f e c t d 
people have been infected with HIV, with 36 million deaths
among individuals with acquired immune deﬁciency syn-
drome (AIDS). Globally, there are approximately 35.3 million
carriers of HIV.2
Co-infection with HBV and HIV is common.3–5 Both viruses
share the same risk factors for infection and can be transmit-
ted through parenteral, sexual, and vertical routes.6 In fact,
it is estimated that 10% of HIV carriers in the world have
chronic hepatitis B.4 The progression of hepatitis B-associated
liver disease is particularly modiﬁed by HIV co-infection. In
HBV/HIV co-infected individuals, the development of chronic
hepatitis B is accelerated, with higher risk of cirrhosis and
hepatocellular carcinoma development, and increased mor-
bidity and mortality rates.7–9 Thus, hepatitis B vaccination
in the United States of America is recommended by the
Advisory Committee on Immunization Practices (ACIP) for all
HIV-infected individuals,10 as a strategy to reduce the public
health burden caused by co-infection with these two viruses.
Several studies have shown an impaired antibody response
to the standard three doses of 20 g HBV vaccine of HBV immu-
nization in HIV-infected patients.11–13 However, a signiﬁcant
higher seroconversion rate was associated with the adminis-
tration of double dose of the classic 0, 1 and 6-month schedule
hepatitis B vaccination among patients with CD4 cell counts
≥350 cells/mm3 and HIV viral load <10,000 copies/mL.13 A
signiﬁcant increase in the seroconversion rate was also
demonstrated in HIV-1 patients using a rapid vaccination
schedule of 40 g HBV vaccine at weeks 0, 4, 8 and 24.14 Fur-
thermore, increased compliance with HBV vaccination was
veriﬁed among HIV-infected patients who received the accel-
erated schedule.15
In addition to differences in compliance patterns and anti-
body responses found with the use of different schedules and
antigen concentrations, individual factors are also associated
with the success of HBV immunization among HIV carriers.16
In this study, the aim was to evaluate the vaccination cover-
age and immunity against HBV among HIV-infected patients
in South Brazil, as well as to identify factors that are associ-
ated with vaccination compliance and antibody reactivity in
the studied population.
Methods
Patients
This cross-sectional study was conducted at Professor Poly-
doro Ernani de São Thiago University Hospital located in
Santa Catarina, South Brazil, between October 2012 and March
2013. The sample consisted of HIV-infected men  and women
receiving free antiretroviral therapy and laboratory monitor-
ing. Universal antiretroviral drugs distribution program was
introduced in Brazil in 1996 aiming to ensure free access to
essential regimens, including protease inhibitors, for all peo-
ple living with HIV. In addition, the Brazilian Ministry of Health
has established the National CD4+/CD8+ T Lymphocyte Count
and Viral Load Laboratory Network to monitor patient thera-
peutic response.17
This study was approved by the Ethics Committee of
the Federal University of Santa Catarina (Protocol 94.398). 1 5;1  9(2):181–186
Informed written consent was obtained from all participants
after having received written information.
All the patients in this study were evaluated for their
HIV viral load and CD4 cell count. Patients were stratiﬁed
according to viral load into three groups (<50 copies/mL,
50–10,000 copies/mL and >10,000 copies/mL) and according
to their CD4 cell count into two groups (<500 cells/L  and
≥500 cells/L). The cut-off of 500 cells/mm3 for the CD4 count
was taken according to the Brazilian Therapeutic Guidelines
for Clinical Management of HIV Infection in Adults.18
The patients answered a self-administered questionnaire,
which comprised the following modules: socio-demographic
characteristics (including sex, age, ethnicity, and socioeco-
nomic status), transmission route of HIV infection, time
since HIV infection diagnosis, and time since initiation of
antiretroviral therapy. The surrogate variables for socioeco-
nomic inequalities were monthly income and highest level of
education in the household.
The study was conducted in order to determine the vacci-
nation coverage based on the evaluation of vaccination cards
and to investigate the association of anti-HBs titers with differ-
ent socio-demographic aspects. The study sample was divided
into three groups (vaccinated, unvaccinated, and possibly
unvaccinated) to estimate the effect of the analyzed variables
on compliance with vaccination schedules.
Patients who had received the hepatitis B vaccine in
the classic three-dose or four double-dose schedules were
included in the vaccinated group. Patients vaccinated before
the HIV diagnosis received the classic three doses of HBV vac-
cine. However, it is not possible to know if those patients
who had received the three-dose schedule (normal regimen)
were HIV-infected at the time of vaccination. On the other
hand, patients vaccinated after HIV diagnosis received the
four double-dose schedule vaccine.
Patients with no vaccination records who had anti-HBs lev-
els higher than 10.0 IU/L and tested negative for HBsAg and/or
antibody to hepatitis B core (anti-HBc) serological markers
were classiﬁed as vaccinated. Those with no vaccination
records who tested positive only for anti-HBc were included
in the unvaccinated group.
Subjects were also tested for their immune status against
HBV, and were classiﬁed according to anti-HBs levels:
≤2.0 IU/L, 2.1–10.0 IU/L, and >10.0 IU/L.
Assessments
A blood sample was collected from each subject for the deter-
mination of anti-HBs concentration. After serum separation,
anti-HBs antibodies were detected by Chemiluminescence
Microparticle Imunoassay (CMIA) using a commercial kit
(ARCHITECT®, Abbott Diagnostics, Sligo, Ireland), according
to the manufacturer’s instructions. CD4 cell count was  deter-
mined with BD FACSCalibur ﬂow cytometer (Biosciences, San
Jose, CA, USA) in units of cells/L. Plasma HIV RNA was quan-
tiﬁed with a branched DNA technique [VERSANT HIV-1 RNA
3.0 (bDNA), Siemens Tarrytown, New York, USA].Statistical  analysis
Pearson’s chi-square test was carried out to examine the asso-
ciation between categorical variables, and a value of p < 0.05
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Table 1 – Socio-demographic characteristics associated with HBV vaccination coverage of HIV-infected patients in South
Brazil.
Variable Unvaccinated Vaccinated Susceptible (possibly
unvaccinated)
p  Total
n % n % n % n %
Total 76 25.3 172 57.3 52 17.3 300 100.0
Age (years)
≤40 18 17.8 65 64.4 18 17.8 101 33.7
41–50 28 25.2 65 58.6 18 16.2 0.118 111 37.0
>50 30 34.1 42 47.7 16 18.2 88 29.3
Gender
Male 54 30.2 102 57.0 23 12.8 0.010* 179 59.7
Female 22 18.2 70 57.8 29 24.0 121 40.3
Ethnicity
White 68 26.4 150 58.1 40 15.5 0.104 258 86.0
Black 8 19.0 22 52.4 12 28.6 42 14.0
Highest level of education
<High school 41 23.4 96 54.9 38 21.7 0.058 175 58.3
≥High school 35 28.0 76 60.8 14 11.2 125 41.7
Monthly income (US$)
<1300 49 24.4 107 53.2 45 22.4 0.004* 201 67.0
≥1300 27 27.3 65 65.7 7 7.1 99 33.0
Time since HIV infection diagnosis (years)
<10 43 26.9 96 60.0 21 13.1 0.119 160 53.3
≥10 33 23.6 76 54.3 31 22.1 140 46.7
Time since initiation of antiretroviral therapy (years)
<10 48 25.5 113 60.1 27 14.4 0.197 188 62.7
≥10 28 25.0 59 52.7 25 22.3 112 37.3
Transmission route of HIV infection
Homosexual 17 25.0 43 63.2 8 11.8 68 22.7
Heterosexual 44 23.8 106 57.3 35 18.9 0.324 185 61.7
Intravenous drug use 13 38.2 16 47.1 5 9.6 34 11.3
Other 2 15.4 7 53.8 4 30.8 13 4.3
HIV viral load (copies/mL)
<50 60 26.2 135 59.0 34 14.8 229 76.4
50– 10,000 9 19.6 25 54.3 12 26.1 0.310 46 15.3
>10,000 7 28.0 12 48.0 6 24.0 25 8.3
CD4 cell count (cells/L)
<500 38 24.8 86 56.2 29 19.0 0.751 153 51.0
≥500 38 25.9 86 58.5 23 15.6 147 49.0
∗ Statistically signiﬁcant at p < 0.05.
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able 1 shows the socio-demographic characteristics asso-
iated with HBV vaccination coverage among HIV-infected
atients in South Brazil. A total of 300 patients were included
n the study and out of them, there were 121 (40.3%)
omen and 179 (59.7%) men. The majority of patients were
ged between 41 and 50 years old (37.0%) and the second
argest category consisted of younger individuals (≤40 years),comprising 33.7% of the study sample. The older age group
(>50 years) comprised 29.3% of the patients (Table 1).
As shown in Table 1, the most common transmission route
of HIV infection was heterosexual contact (61.7%), followed by
homosexual contact (22.7%), intravenous drug use (11.3%), and
others (4.3%).
Table 2 shows HBV vaccination coverage and antibody titers
among the HIV-infected patients. The overall HBV vaccina-
tion coverage in the studied sample was 57.4%, and 56.7%
had anti-HBs titers >2.0 IU/L; 47.0% had antibody levels higher
than 10 IU/L (Table 2). The susceptible group (possibly unvac-
cinated) consisted of patients who did not have a vaccination
card at the time of the study, and showed negative HBV sero-
logical markers. Among patients who had received hepatitis
184  b r a z j i n f e c t d i s . 2 0 1 5;1  9(2):181–186
Table 2 – Hepatitis B vaccination coverage and antibody titers among the HIV-infected patients.
Vaccination status Serum anti-HBs
≤2.0 IU/L 2.1–10.0 IU/L >10.0 IU/L Total
n % n % n % n %
Unvaccinated 32 10.7 6 2.0 38 12.7 76 25.3
Vaccinated 46 15.3 23 7.7 103 34.3 172 57.4
Susceptible (possibly unvaccinated) 52 17.3 – – – – 52 17.3
9 Total 130 43.3 2
B vaccine, anti-HBs seropositivity was 73.2% (126/172). Of the
76 unvaccinated individuals, 44 (57.9%) had a positive anti-
HBs result. All unvaccinated patients with anti-HBs >2.0 IU/L
showed a positive test for anti-HBc, a marker of hepatitis B
virus infection (Table 2).
In this study, anti-HBs was found to be negative (≤2.0 IU/L)
in 55.4% (67/121) of woman and in 35.2% (63/179) of man.
Male gender was signiﬁcantly associated with high levels of
serum antibody (p < 0.05). High levels of anti-HBs among HIV-
infected patients were also associated with high monthly
income (p = 0.005). On the other hand, concentration of anti-
HBs was not associated with age, CD4 cell count, and HIV viral
load (p > 0.05).
According to the socio-demographic characteristics of the
studied patients shown in Table 1, the HBV vaccination cov-
erage among the females was 57.8% (70/121), whereas 57.0%
(102/179) of men  had received the vaccine. The majority of
the unvaccinated subjects was male and had lower monthly
income than the vaccinated individuals (Table 1). On the other
hand, women were identiﬁed as more  likely to be possibly
unvaccinated than men  (24.0% versus 12.8%, respectively).
Compliance with vaccination against HBV was not asso-
ciated with age, ethnicity, level of education, time since HIV
diagnosis or initiation of antiretroviral therapy, and transmis-
sion route of HIV infection (p > 0.05) (Table 1).
Discussion
In Brazil, vaccination against HBV was included in the National
Immunization Program in 1996, to high-risk individuals and
children younger than one year old. In 2001, the immunization
against HBV has been expanded to young people up to 19 years
of age.19 Recently, the Brazilian Ministry of Health has again
expanded the free vaccination program to individuals up to 49
years old,20 in addition to all HIV-infected patients.21 For HIV
carriers, the vaccination schedule of 0, 1, 2 and 6–12 months
is recommended, with twice the dose used in the standard
protocol.22
The overall coverage of HBV vaccine found in this study
(57.4%) was lower than that previously reported among
healthy individuals in South Brazil (87.6–97.5%).23–25 This may
possibly be consequence of the lack of information concern-
ing hepatitis B vaccination among HIV-infected patients and
healthcare professionals. On the other hand, the coverage rate
found in this study is similar to the coverage rate (58.2%) esti-
mated among HIV-infected individuals attending 13 centers
for HIV care in the United Kingdom.269.7 141 47.0 300 100.0
In this study, compliance with hepatitis B vaccination
schedule was signiﬁcantly associated with gender. In con-
trast to other studies on immunization against HBV in HIV
carriers,15,27,28 male sex was found to be a predictor of high
titers of anti-HBs.
With respect to the immune status, the proportion of
subjects with anti-HBs antibody levels higher than 10 IU/L
reported in the present study (47.0%) is in agreement with
that veriﬁed among healthy vaccinees of the southern Brazil-
ian region (41.0–58.8%).23–25,29,30 However, it is important to
point out that the comparison of results is difﬁcult as the
maintenance of anti-HBs titers may be inﬂuenced by the time
elapsed since vaccination and the level of exposure to hepati-
tis B virus.31
The rates of HIV-infected individuals who develop anti-HBs
levels ≥10 IU/L after receiving the standard, accelerated, or
four double-dose schedules are variable, ranging from 38.7%
to 91.0%.15,16,32 Several studies have shown an association
between low-level viremia and better antibody response to
HBV vaccination in HIV-infected individuals.12,33,34 In a report
comparing the standard and accelerated HBV vaccination
schedules among HIV carriers, the use of antiretroviral therapy
and HIV-RNA control were associated with enhanced response
and development of an anti-HBs titer ≥10 IU/L in both vacci-
nation protocols.15
Our results have shown that anti-HBs antibody titers were
not signiﬁcantly associated with CD4 cell count. In agreement
with previous observations,35 greater CD4 suppression did not
impair antibody reactivity in the studied patients. On the other
hand, other ﬁndings demonstrated an association between
successful immunization against HBV and high CD4 level.11,36
The CD4 cell count has also been reported as a factor asso-
ciated with antibody responses to different HBV vaccination
schedules.16
In the present study, the income disparity was found to be
signiﬁcantly associated with the outcome of hepatitis B vac-
cination. Although no association was veriﬁed with level of
education, either the vaccination coverage or anti-HBs titers
were lower in HIV-infected individuals with lower monthly
income. In addition, the patients living on less than US$  1300
a month were more  likely to be susceptible to HBV infec-
tion (possibly non-vaccinated). These data are of concern and
emphasize the importance of public health actions directed
toward low-income populations. As a result of the lower con-
sumption of health services among poorer populations in
Brazil, there is an increase in the framework of social inequal-
ity. Low income generates poorer health, and poorer health
results in high levels of unemployment and social exclusion.37
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In conclusion, our results point toward the need for
mprovement in the HBV vaccination coverage among HIV
arriers in the southern Brazilian region, in particular focus-
ng on low-income individuals. The signiﬁcant inequality in
he coverage rates and antibody reactivity in favor of patients
ith better economic status highlights the requirement for the
evelopment of public strategies in order to increase the avail-
bility of healthcare services for poorer population strata. In
his regard, the implementation of policies focused on increas-
ng the access to vaccination services might help establishing
 successful hepatitis B immunization program among HIV
arriers.
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